Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Odimma Logo
Odimma Growth Score
57
CB Rank
134243
Heat Score
51
Odimma is a biotech company that focuses on precision medicine and cure for personalized cancer immunotherapy.
Founded
obfuscation
PrivateSeed Illkirch-graffenstaden, Alsace, France1-10 www.odimma-therapeutics.com/
Biotechnology
Health Care
Life Science
Precision Medicine
Therapeutics
Overview

Odimma
Total Funding
obfuscation
Growth Score
57
Heat Score
51

Total Funding
obfuscation
obfuscation
Seed raised
obfuscation
Growth Score57
-2 pts
in past quarter
Heat Score 51
-8 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Events
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Odimma

CB Rank
134243
Odimma is a biotech company that focuses on precision medicine and cure for personalized cancer immunotherapy.
Founded
obfuscation
PrivateSeed Illkirch-graffenstaden, Alsace, France1-10 www.odimma-therapeutics.com/
Biotechnology
Health Care
Life Science
Precision Medicine
Therapeutics

Funding Rounds

Seed
OBF
in
obfuscation

Key People

Details

Legal Name Odimma Therapeutics SAS
Operating Status Active
Company Type For Profit
Founders  Jessica Matta
Contact Email contact@odimma-therapeutics.com
Predictions & Insights

Growth Prediction

See this Growth Prediction

Products & Services

Personalized Immunotherapy Platform
A precision immunotherapy platform that uses AI and synthetic DNA technology to induce cellular immune responses targeting specific tumor markers in cancer patients.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 1
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Seed Round - Odimma Logo
Seed Round - Odimma
4
obfuscation
— Seed
obfuscation
Seed Round - Odimma Logo
Seed Round - Odimma
4
obfuscation
— Seed
obfuscation
Seed Round - Odimma Logo
Seed Round - Odimma
4
obfuscation
— Seed
obfuscation
Seed Round - Odimma Logo
Seed Round - Odimma
4
obfuscation
— Seed
obfuscation
Seed Round - Odimma Logo
Seed Round - Odimma
4
obfuscation
— Seed

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 1
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Seed Round - Odimma Logo
Seed Round - Odimma
4
obfuscation
— Seed
obfuscation
Seed Round - Odimma Logo
Seed Round - Odimma
4
obfuscation
— Seed
obfuscation
Seed Round - Odimma Logo
Seed Round - Odimma
4
obfuscation
— Seed
obfuscation
Seed Round - Odimma Logo
Seed Round - Odimma
4
obfuscation
— Seed
obfuscation
Seed Round - Odimma Logo
Seed Round - Odimma
4
obfuscation
— Seed

Investors

Market Intelligence
People
View Profiles & Contacts
Headcount 1-10 Employee Profiles 1

Employee Profiles

News

News and Press

News•Jul 23, 2023
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 5, 2023
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Mar 27, 2023
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Dec 7, 2022
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

146
121.21%
 in past month

IT Spend

$58.5KThis year, Odimma is projected to spend $58.5K on IT, according to Aberdeen.

Active Website Tech Count

27Odimma is actively using 27 technologies for its website, according to BuiltWith. These include SPF, Google Font API, and  Apple Mobile Web Clips Icon.

Total IP

4Odimma has registered 4 trademarks with the most popular class being 'Pharmaceutical, veterinary and sanitary products', according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is Odimma's headquarters? Odimma is located in Illkirch-graffenstaden, Alsace, France.Who invested in Odimma? Odimma has 4 investors including Alsace Business Angels and  Capital Grand Est.When was the last funding round for Odimma? Odimma closed its last funding round on
obfuscation
from a Seed round.Who are Odimma's competitors? Alternatives and possible competitors to Odimma may include Moderna, Bristol-Myers Squibb, and  BioNTech.How much funding has Odimma raised to date? Odimma has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(8ea058e 1)
|